Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Overview
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Companies Involved in Therapeutics Development
Bristol-Myers Squibb Co
Chong Kun Dang Pharmaceutical Corp
DalCor Pharmaceuticals Inc
NewAmsterdam Pharma BV
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Drug Profiles
CKD-508 – Drug Profile
Product Description
Mechanism Of Action
History of Events
dalcetrapib – Drug Profile
Product Description
Mechanism Of Action
History of Events
HL-16 – Drug Profile
Product Description
Mechanism Of Action
obicetrapib – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit CETP for Cardiovascular Disease – Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit CETP for Dyslipidemia – Drug Profile
Product Description
Mechanism Of Action
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Dormant Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Discontinued Products
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals
May 19, 2022: NewAmsterdam pharma to present at upcoming medical conferences new post-Hoc alyses from phase 2 ROSE trial of obicetrapib in patients with dyslipidemia
May 11, 2022: New Meta-Alysis in European Heart Jourl’s Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors’ Role in Reduction of Diabetes Risk
Apr 05, 2022: NewAmsterdam Pharma doses first patient in phase 2 trial of Obicetrapib in combition with Ezetimibe as an adjunct to high-intensity statin therapy
Mar 01, 2022: NewAmsterdam Pharma doses first patient in PREVAIL, the cardiovascular outcomes trial of obicetrapib in adults with atherosclerotic cardiovascular disease (ASCVD)
Feb 14, 2022: New review article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) inhibition’s role in reducing cardiovascular disease risk
Jan 04, 2022: NewAmsterdam Pharma doses first patient in phase 3 BROADWAY trial of obicetrapib in adults with heterozygous familial hypercholesterolemia (HeFH) and/or established atherosclerotic cardiovascular disease (ASCVD)
Nov 15, 2021: NewAmsterdam Pharma reports positive data in Phase II dyslipidemia trial
Nov 08, 2021: NewAmsterdam Pharma announces ROSE phase 2 trial results accepted for Featured Science Presentation at 2021 AHA Scientific Sessions
Jul 28, 2021: NewAmsterdam Pharma reports positive results from phase 2 study of Oral Obicetrapib demonstrating over 50% LDL-lowering as an adjunct to high-intensity statins
Jul 27, 2020: DalCor announces dal-GenE trial continues with fil data expected in the first half of 2021
Jan 27, 2020: Dalcor announces Dal-gene trial to continue as planned following interim futility alysis
Dec 17, 2018: Dalcor announces completion of patient enrollment in Dal-gene, the first phase 3 precision medicine cardiovascular outcomes trial in corory heart disease
Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile
Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Pipeline by DalCor Pharmaceuticals Inc, 2022
Pipeline by NewAmsterdam Pharma BV, 2022
Dormant Projects, 2022
Discontinued Products, 2022
Discontinued Products, 2022 (Contd..1)
Discontinued Products, 2022 (Contd..2)